Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veverimer - Tricida

Drug Profile

Veverimer - Tricida

Alternative Names: TRC-101; Veverimer

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tricida
  • Class Diamines; Polymers; Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Renal failure

Most Recent Events

  • 15 Nov 2019 US FDA accepts NDA for veverimer for Renal failure for review under the Accelerated Approval Programme
  • 14 Nov 2019 The USFDA plans to hold Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to discuss the New Drug Application of veverimer in the first half of 2020
  • 14 Nov 2019 Tricida expects approval of veverimer in August 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top